Potential of RAS inhibition to improve metabolic bone disorders - Wikidata - awgldk - TriplyDB

Potential of RAS inhibition to improve metabolic bone disorders

Potential of RAS inhibition to improve metabolic bone disorders

http://www.wikidata.org/entity/Q26866515

about

Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease.ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.Role of mesenchymal stem cells versus angiotensin converting enzyme inhibitor in kidney repair.Aliskiren has chondroprotective efficacy in a rat model of osteoarthritis through suppression of the local renin-angiotensin system.Effects of losartan treatment on the physicochemical properties of diabetic rat bone.

P2860

Q38193086-4B9A1778-BC9C-484B-8A64-2573EABE0685 Q38970231-F4C3FAD2-BE6E-4F0C-95CA-D1885D4C3C21 Q39780663-2CE3E500-220C-49ED-B022-071641A73BD6 Q42679493-B733CA47-036F-461A-82BD-6F5AD3EED68B Q51398203-92961440-B572-43AB-A707-C5AD0EB057A8

P2860

Potential of RAS inhibition to improve metabolic bone disorders

http://www.wikidata.org/entity/Q26866515

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Potential of RAS inhibition to improve metabolic bone disorders

@ast

Potential of RAS inhibition to improve metabolic bone disorders

@en

Potential of RAS inhibition to improve metabolic bone disorders

@nl

type

label

Potential of RAS inhibition to improve metabolic bone disorders

@ast

Potential of RAS inhibition to improve metabolic bone disorders

@en

Potential of RAS inhibition to improve metabolic bone disorders

@nl

prefLabel

Potential of RAS inhibition to improve metabolic bone disorders

@ast

Potential of RAS inhibition to improve metabolic bone disorders

@en

Potential of RAS inhibition to improve metabolic bone disorders

@nl

P1433

Q26866515-F7F12FBE-5418-42D5-8D16-76BF29806081

P1476

Q26866515-8CCE0540-53C3-41AF-9DDE-9E183316E6F4

P2093

Q26866515-00451AD6-0626-4232-ADCA-0B65CE7DFECE

Q26866515-1BD5041C-6376-40F2-A01B-46A5AF2D5F86

Q26866515-322C51F8-08B9-4CB5-AD3D-324F69A263FC

Q26866515-3971968B-4A24-40BD-821B-129EA38D59EC

Q26866515-B70C6097-5BCE-461B-AAB0-679B4C09444E

P275

Q26866515-D2CD8AF7-6681-491A-B427-80154D768CE4

P2860

Q26866515-0D195981-0621-40BD-853B-B1EA7E41BB4B

Q26866515-0E6DF9C3-F052-400B-93C4-00B18823B9B8

Q26866515-1BBA1E71-DFF4-4FAE-B5C8-B167E5434C45

Q26866515-2BAF521B-D9C6-4A8E-AE6D-C138E6F14714

Q26866515-2DF94ED1-F3A8-4A11-AA55-5B9EAA8C6285

Q26866515-3DFC1E56-320D-403D-B1AD-DB9161B4B188

Q26866515-500D5AAC-2929-4680-86CA-D3BC100E7CF5

Q26866515-5898E96F-0BCF-4A4D-B9EE-EA7A25415E5A

Q26866515-5CDC2F7D-FB23-4050-BA51-A7C995F8AA83

Q26866515-5D0A16A0-ADB9-4483-8A86-9E493B5A07E3

P304

Q26866515-CFD84859-0268-42F7-831C-87ABE026FB25

P31

Q26866515-4D41F744-9406-4531-897E-53DB4C0A7E65

Q26866515-FC0F35BC-CA6B-4611-897B-525CED148AE2

P356

Q26866515-450197C0-7039-4F8F-894C-20341591FDAA

P407

Q26866515-C3C3E3E2-BB07-4F12-8FD1-34A199E69AED

P478

Q26866515-D5E72974-8E30-4FD9-9F90-7C9AAD716719

P5008

Q26866515-62043FC3-5EB6-4138-8DD6-F37E81A88688

P577

Q26866515-6FB96FD4-806B-4DCA-AF64-3A65C8FBC300

Q26866515-7907FF44-B251-4296-90AE-DCE1DA0AABCD

P5875

Q26866515-8A81E63F-6D6C-4C04-9B4C-1BA0898F04AC

P698

Q26866515-98B3B92E-E412-4750-9A0F-AD70DAA87571

P921

Q26866515-3AE3C362-0F76-43B5-80CA-A8871C2A8491

Q26866515-6CB145D2-8CCD-4AEA-830E-B98FEF056E88

Q26866515-90BFA790-C571-4EE8-AA67-38E1BE8D7C24

Q26866515-C6C93172-3D3D-472C-B2E5-D29167CD0073

Q26866515-FD2BAB5C-04A3-4219-BE00-7D0E496AAE71

P932

Q26866515-7FD56789-C218-440D-8814-71A00C62692A

P356

P1433

BioMed Research International

P1476

Potential of RAS inhibition to improve metabolic bone disorders

@en

P2093

Emmanuel Mukwaya

http://www.w3.org/2001/XMLSchema#string

Hai Pan

http://www.w3.org/2001/XMLSchema#string

Teng-Yue Diao

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

Yoseph Gebru

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

Bone resorption by osteoclasts

Structure-based design of aliskiren, a novel orally effective renin inhibitor

Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells.

Angiotensin II type 1 receptor blockers.

The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment.

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related oste

Renin inhibition with aliskiren: where are we now, and where are we going?

Genetic regulation of bone mass and susceptibility to osteoporosis.

P304

932691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/932691

http://www.w3.org/2001/XMLSchema#string

P407

P478

2013

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256086245

http://www.w3.org/2001/XMLSchema#string

P698

23971050

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

biomedical investigative technique

metabolic bone disease

human musculoskeletal system

P932

3736485

http://www.w3.org/2001/XMLSchema#string